Almirall

What Almirall does

Almirall, S.A. is a publicly traded pharmaceutical company (BME: ALM) headquartered in Barcelona, Spain, founded in 1943 and family-controlled by the Gallardo family. The company is fully dedicated to medical dermatology, developing and commercializing prescription biologic, small-molecule, and topical therapies for inflammatory and pre-cancerous skin conditions including atopic dermatitis, psoriasis, actinic keratosis, acne, onychomycosis, hidradenitis suppurativa, and rare skin diseases. Its commercial portfolio centers on two anchor biologics — Ilumetri (tildrakizumab, IL-23 inhibitor) and Ebglyss (lebrikizumab, IL-13 inhibitor, in-licensed from Eli Lilly for Europe) — supplemented by Klisyril/Klisyri (tirbanibulin) for actinic keratosis, Seysara (sarecycline) for acne, and Jublia (efinaconazole) for onychomycosis.

Underlying technology includes AI/ML-enabled drug discovery platforms developed with Microsoft (a dermatology-specific AI platform, Feb 2024) and Evotec (multi-target alliance for immune-mediated skin diseases), bispecific antibody constructs (e.g., anti-IL-13/OX-40L), an intratumoral mRNA/LNP platform with etherna (LAD-116 for non-melanoma skin cancer), and generative chemistry partnerships with Iktos. R&D also leverages academic collaborations with the University of Dundee, University of Michigan, IRB Barcelona, CRG, and Inserm Transfert.

The business model is prescription pharmaceutical sales to healthcare systems across Europe (Germany, UK, France, Italy, Spain, Poland, Czechia, Slovakia), the US (post-2018 Allergan dermatology acquisition), and now China (new Shanghai entity plus multiple local partnerships), complemented by licensing and royalty income (e.g., the Evotec alliance with up to €230M per program in milestones). Go-to-market is executed through field sales teams, medical science liaisons, and scientific events such as the annual Skin Academy, with revenue recognized on prescription dispensing rather than direct consumer sales. FY2025 net sales reached €1,108.1 million (+12.4% YoY) with EBITDA of €232.9 million, marking the company's first year above the €1 billion threshold.

Name

Almirall

Legal name

Almirall, S.A.

Website

https://almirall.com

Company type

Public

Founded year

1943

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Almirall is a Barcelona-based pharmaceutical company fully dedicated to medical dermatology, developing and commercializing prescription biologic and topical therapies for inflammatory and pre-cancerous skin diseases across 100+ countries, with a portfolio anchored by Ilumetri, Ebglyss, and Klisyri.

Ownership category

akta.pro rank

Product category

Medical Dermatology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermatology & Topical Skin Treatments (HLAIADAE), Topical & Dermatology Generics (HLAIABAE)

Keywords

• Medical dermatology pharmaceuticals
• Biologic skin therapies
• Atopic dermatitis treatment
• Plaque psoriasis medication
• Actinic keratosis therapy

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue from prescription pharmaceutical products including biologics (Ebglyss, Ilumetri) and small molecule drugs sold to healthcare systems across Europe and international markets.
2. Licensing and Royalty Revenue: Out-licensing arrangements generating milestone payments and royalties on net sales, including partnerships with Evotec (up to €230M per program plus royalties) and in-bound licensing arrangements.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels4 records

Core offering

Almirall is a pharmaceutical company that develops, manufactures, and commercializes prescription medications exclusively for medical dermatology. Its portfolio includes biologic therapies such as Ebglyss (lebrikizumab) for atopic dermatitis and Ilumetri (tildrakizumab) for psoriasis, alongside topical and small-molecule treatments like Klisyri/Klisyril (tirbanibulin) for actinic keratosis, Seysara (sarecycline) for acne, and Jublia (efinaconazole) for onychomycosis. Products are sold to healthcare professionals, dermatologists, and healthcare systems across Europe and international markets, with regulatory approvals and reimbursement negotiated country by country.

Product overview

Almirall is a global pharmaceutical company fully dedicated to medical dermatology, operating as a single-focused pharmaceutical developer rather than a platform product company. The company's portfolio centers on biologic drugs and topical treatments for inflammatory and pre-cancerous skin conditions, with Ilumetri (tildrakizumab) and Ebglyss (lebrikizumab) as key growth drivers in its European biologics franchise. Supporting products include Klisyri (tirbanibulin) for actinic keratosis, Seysara (sarecycline) for acne, and Jublia (efinaconazole) for onychomycosis. The company also maintains an open innovation platform (AlmirallShare) for external R&D partnerships and has strategic collaborations with Microsoft for AI-powered drug discovery and Evotec for immunology research.

Differentiator

Problem solved

Functional benefit

Brands

• Ebglyss (lebrikizumab): Biologic treatment for moderate-to-severe atopic dermatitis
• Ilumetri (tildrakizumab)
• Klisyri (tirbanibulin)
• Jublia
• Seysara
• AlmirallShare
• Skin Academy
• Hats On For AK
• Skin Scouts

Products and services

• Ebglyss (lebrikizumab)

Quantifiable outcome

• Ebglyss (lebrikizumab) achieved €110.8 million in FY2025, tripling from prior year, with 63% of patients achieving EASI-75 in Phase 3 pediatric trials
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

23 partnerships are on record, tiered core, supporting and major.

• Shanghai Huaota Biopharmaceutical (Zhejiang Huahai Pharmaceutical)coreStrategic or Co-development Partner · 27 March 2026Collaboration and licensing agreement for a novel-targeted monoclonal antibody candidate for multiple therapeutic indications in medical dermatology. Huaota leads early-stage research and initial clinical development in China while Almirall retains global development and commercialization rights outside China. Deal potentially worth up to USD 340 million in upfront payments, development and commercial milestones, and tiered royalties.
• Simcere Pharmaceutical GroupcoreStrategic or Co-development Partner · 13 March 2026Collaboration with Simcere for IL-2 mutant fusion protein (SIM0278) for alopecia areata and atopic dermatitis. Drug has progressed to Phase II clinical trials in both China and the United States. Almirall expanding commercial presence in China through this partnership as well as separate arrangements with Cutia (topical finasteride) and Sinomune (sarecycline).
• The Skin Cancer FoundationsupportingGTM or Marketing Partner · 24 May 2025Co-founding partner of Hats On For AK campaign launched in 2025 for actinic keratosis awareness, promoting sun protection, early detection, and preventive measures. Campaign addresses the underrecognition of AK, a common pre-cancerous condition estimated to affect over 58 million Americans.
• MicrosoftcoreTechnology or Integration · 1 February 2024Partnership with Microsoft to develop an AI-powered drug discovery platform specifically for dermatology, leveraging Microsoft's AI and cloud infrastructure capabilities. Collaboration aims to accelerate identification and development of novel dermatology treatments through advanced computational methods.
• Evotec SEcoreStrategic or Co-development Partner · 1 May 2022Multi-target drug discovery alliance for immune-mediated inflammatory skin diseases. Evotec's integrated AI/ML-enhanced discovery and preclinical development platforms progress novel candidates from initial leads to preclinical development candidate within approximately two years. Includes undisclosed upfront payments, research payments, and success-based milestones potentially worth up to €230 million per program plus royalties on net sales in the high single-digit percentage range. Collaboration entered May 2022.
• Eli Lilly and CompanycoreChannel Partner/ Reseller/ DistributorAlmirall commercializes Ebglyss (lebrikizumab) in Europe. Eli Lilly develops and manufactures the drug while Almirall holds European rights. Lebrikizumab showed positive Phase 3 pediatric trial results (ADorable-1) in children 6 months to <18 years with 63% achieving EASI-75. Almirall reported €110.8 million sales for FY2025 (more than triple prior year). Eli Lilly plans $3 billion China investment for diabetes/obesity treatments.
• Sun PharmacoreChannel Partner/ Reseller/ DistributorAlmirall commercializes Ilumetri (tildrakizumab) in Europe under license from Sun Pharma. IL-23p19 inhibitor reached €234.4 million sales in FY2025 (+12.3% YoY) with peak sales target above €300 million in Europe. Almirall presented six tildrakizumab posters at AAD 2026 alongside Sun Pharma.
• EthernamajorStrategic or Co-development PartnerMulti-target alliance to develop mRNA-based therapies for dermatology. Almirall nominated LAD-116 as a novel intratumoral mRNA/LNP therapy candidate for non-melanoma skin cancer, advancing from preclinical development toward clinical testing. Collaboration focuses on manufacturing GMP-grade material for IND-enabling studies and Phase I clinical trials.
• AbscimajorTechnology or IntegrationAI drug discovery partnership with Absci to rapidly develop novel dermatology treatments. Almirall and Absci expanded collaboration adding a second program. Absci leverages machine learning and automation for antibody design and drug discovery, positioning Almirall at the intersection of AI and biotechnology.
• Barcelona Supercomputing Center (BSC)supportingTechnology or IntegrationCollaboration with Barcelona Supercomputing Center and Nostrum Biodiscovery to advance computational capabilities for dermatology drug discovery, leveraging supercomputing resources and AI-driven molecular design.
• Ichnos SciencessupportingStrategic or Co-development PartnerLicensing agreement for first-in-class anti-IL-1RAP monoclonal antibody, expanding Almirall's early-stage biologics pipeline in medical dermatology.
• Novo NordisksupportingStrategic or Co-development PartnerLicensed anti-IL-21 monoclonal antibody from Novo Nordisk for development in dermatology. Almirall expanding its IL-targeting portfolio with this novel mechanism.
• EpiMab BiotherapeuticssupportingStrategic or Co-development PartnerBispecific antibody licensing agreement for dermatology applications, complementing Almirall's internal bispecific development program targeting IL-13 and OX-40L.
• IktossupportingTechnology or IntegrationAI-powered generative drug design research collaboration using Iktos's computational chemistry and synthesis planning technology to accelerate novel dermatology compound identification.
• Centre for Genomic Regulation (CRG)supportingStrategic or Co-development PartnerResearch collaboration to develop and characterize novel targets for inflammatory skin diseases, leveraging genomic research capabilities.
• Happify HealthsupportingStrategic or Co-development PartnerStrategic partnership to develop digital therapeutics supporting psoriasis patients, combining Almirall's pharmaceutical treatments with digital health solutions for holistic patient care.
• IRB BarcelonasupportingStrategic or Co-development PartnerResearch collaboration to discover novel therapeutic targets for dermatology, leveraging IRB Barcelona's biomedical research expertise.
• University of MichigansupportingStrategic or Co-development PartnerResearch collaboration to gain understanding of disease mechanisms in inflammatory skin conditions, supporting Almirall's target identification and validation efforts.
• University of DundeesupportingStrategic or Co-development PartnerMulti-target research collaboration with University of Dundee to discover and develop novel dermatology treatments, combining academic research capabilities with Almirall's development expertise.
• Inserm TransfertsupportingStrategic or Co-development PartnerLicensing and research collaboration leveraging Inserm's academic research capabilities in dermatology for novel target identification and validation.
• CutiasupportingChannel Partner/ Reseller/ DistributorPartnership with Cutia to market topical finasteride in China, expanding Almirall's commercial dermatology presence in the Chinese market.
• SinomunesupportingChannel Partner/ Reseller/ DistributorPartnership with Sinomune to market sarecycline in China, complementing Almirall's product portfolio expansion in the Chinese dermatology market.
• ParateksupportingChannel Partner/ Reseller/ DistributorSeysara (sarecycline) licensing agreement for China market. Almirall obtained rights for China development and commercialization of this acne treatment.

Scale indicators19 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Galderma: Galderma is a pure-play dermatology company offering prescription, aesthetics, and consumer skin health products. It is the most direct peer to Almirall given its singular focus on dermatology across biologics, topicals, and aesthetics, competing head-to-head with Klisyri and other portfolio assets.
• LEO Pharma: LEO Pharma is a Danish dermatology-focused pharmaceutical company with prescription treatments for psoriasis, atopic dermatitis, and actinic keratosis. Directly comparable to Almirall as a specialty dermatology peer serving similar European HCP and patient segments.

Broad incumbents

• AbbVie: AbbVie competes with Almirall through Skyrizi (IL-23 inhibitor for psoriasis, competing with Ilumetri) and Rinvoq (oral JAK inhibitor for atopic dermatitis, competing with Ebglyss). AbbVie is a broad incumbent with a major dermatology franchise and significantly larger resources.
• Sanofi: Sanofi (with Regeneron) markets Dupixent, the market-leading IL-4/13 biologic for atopic dermatitis that directly competes with Almirall's Ebglyss. Sanofi is a broad incumbent with deep dermatology and immunology capabilities.
• Pfizer: Pfizer competes with Almirall via Cibinqo (JAK inhibitor for atopic dermatitis) and Litfulo (JAK inhibitor for alopecia areata). Broad incumbent pharma with significant dermatology commercial reach and competing biologics/orals in the same indications.
• Bristol Myers Squibb: BMS markets Sotyktu (TYK2 inhibitor) for psoriasis, competing with Almirall's Ilumetri. As a broad incumbent, BMS represents competitive pressure in dermatology with significant R&D and commercial scale.
• UCB: UCB markets Cimzia (for hidradenitis suppurativa and inflammatory skin conditions) and is developing assets in dermatology. Broad incumbent with overlapping inflammatory skin disease franchises.

Others

• Eli Lilly: Eli Lilly is both a development/manufacturing partner for Ebglyss (Almirall holds European rights) and a competitor through its broader immunology pipeline. The relationship makes Lilly a strategic peer with overlapping atopic dermatitis ambitions.
• Sun Pharma: Sun Pharma is both the originator/development partner for Ilumetri (tildrakizumab) and a broader Indian generics and specialty pharma company. Their commercial licensing relationship makes Sun Pharma a strategic peer with aligned interests in tildrakizumab's European success.

Emerging players

• Arcutis Biotherapeutics: Arcutis is a US-based emerging dermatology company with topical treatments for psoriasis, atopic dermatitis, and seborrheic dermatitis. Comparable as a focused dermatology player with innovative topical formulations targeting inflammatory skin conditions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/almirall

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almirall